These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 28794111)

  • 1. Clinical Characteristics and Long-Term Outcome of Hypertrophic Cardiomyopathy in Individuals With a MYBPC3 (Myosin-Binding Protein C) Founder Mutation.
    van Velzen HG; Schinkel AFL; Oldenburg RA; van Slegtenhorst MA; Frohn-Mulder IME; van der Velden J; Michels M
    Circ Cardiovasc Genet; 2017 Aug; 10(4):. PubMed ID: 28794111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertrophic cardiomyopathy in myosin-binding protein C (
    Adalsteinsdottir B; Burke M; Maron BJ; Danielsen R; Lopez B; Diez J; Jarolim P; Seidman J; Seidman CE; Ho CY; Gunnarsson GT
    Open Heart; 2020; 7(1):e001220. PubMed ID: 32341788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A founder MYBPC3 mutation results in HCM with a high risk of sudden death after the fourth decade of life.
    Calore C; De Bortoli M; Romualdi C; Lorenzon A; Angelini A; Basso C; Thiene G; Iliceto S; Rampazzo A; Melacini P
    J Med Genet; 2015 May; 52(5):338-47. PubMed ID: 25740977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nationwide study on hypertrophic cardiomyopathy in Iceland: evidence of a MYBPC3 founder mutation.
    Adalsteinsdottir B; Teekakirikul P; Maron BJ; Burke MA; Gudbjartsson DF; Holm H; Stefansson K; DePalma SR; Mazaika E; McDonough B; Danielsen R; Seidman JG; Seidman CE; Gunnarsson GT
    Circulation; 2014 Sep; 130(14):1158-67. PubMed ID: 25078086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phenotypic spectrum of the first Belgian
    Boen HM; Alaerts M; Van Laer L; Saenen JB; Goovaerts I; Bastianen J; Koopman P; Vanduynhoven P; De Vuyst E; Rosseel M; Heidbuchel H; Van Craenenbroeck EM; Loeys B
    Front Genet; 2024; 15():1392527. PubMed ID: 38836037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Founder mutation in myosin-binding protein C with an early onset and a high penetrance in males.
    Méndez I; Fernández AI; Espinosa MÁ; Cuenca S; Lorca R; Rodríguez JF; Tamargo M; García-Montero M; Gómez C; Vilches S; Vázquez N; Álvarez R; Medrano C; Yotti R; Fernández-Avilés F; Bermejo J
    Open Heart; 2021 Sep; 8(2):. PubMed ID: 34588271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy.
    Chida A; Inai K; Sato H; Shimada E; Nishizawa T; Shimada M; Furutani M; Furutani Y; Kawamura Y; Sugimoto M; Ishihara J; Fujiwara M; Soga T; Kawana M; Fuji S; Tateno S; Kuraishi K; Kogaki S; Nishimura M; Ayusawa M; Ichida F; Yamazawa H; Matsuoka R; Nonoyama S; Nakanishi T
    Heart Vessels; 2017 Jun; 32(6):700-707. PubMed ID: 27885498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations.
    Michels M; Soliman OI; Kofflard MJ; Hoedemaekers YM; Dooijes D; Majoor-Krakauer D; ten Cate FJ
    JACC Cardiovasc Imaging; 2009 Jan; 2(1):58-64. PubMed ID: 19356534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gender differences in the clinical features of hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations.
    Terauchi Y; Kubo T; Baba Y; Hirota T; Tanioka K; Yamasaki N; Furuno T; Kitaoka H
    J Cardiol; 2015 May; 65(5):423-8. PubMed ID: 25123604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of Phenotypic Differences by Cardiovascular Magnetic Resonance Imaging in MYH7 (β-Myosin Heavy Chain)- Versus MYBPC3 (Myosin-Binding Protein C)-Related Hypertrophic Cardiomyopathy.
    Weissler-Snir A; Hindieh W; Gruner C; Fourey D; Appelbaum E; Rowin E; Care M; Lesser JR; Haas TS; Udelson JE; Manning WJ; Olivotto I; Tomberli B; Maron BJ; Maron MS; Crean AM; Rakowski H; Chan RH
    Circ Cardiovasc Imaging; 2017 Feb; 10(2):. PubMed ID: 28193612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel phenotype-genotype correlations of hypertrophic cardiomyopathy caused by mutation in α-actin and myosin-binding protein genes in three unrelated Chinese families.
    Yang QL; Bian YY; Wang B; Zuo L; Zhou MY; Shao H; Zhang YM; Liu LW
    J Cardiol; 2019 May; 73(5):438-444. PubMed ID: 30600190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonfamilial Hypertrophic Cardiomyopathy: Prevalence, Natural History, and Clinical Implications.
    Ingles J; Burns C; Bagnall RD; Lam L; Yeates L; Sarina T; Puranik R; Briffa T; Atherton JJ; Driscoll T; Semsarian C
    Circ Cardiovasc Genet; 2017 Apr; 10(2):. PubMed ID: 28408708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myocardial Deformation Analysis in
    Höller V; Seebacher H; Zach D; Schwegel N; Ablasser K; Kolesnik E; Gollmer J; Waltl G; Rainer PP; Verheyen S; Zirlik A; Verheyen N
    Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical features, spectrum of causal genetic mutations and outcome of hypertrophic cardiomyopathy in South Africans.
    Ntusi NA; Shaboodien G; Badri M; Gumedze F; Mayosi BM
    Cardiovasc J Afr; 2016; 27(3):152-158. PubMed ID: 27841901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac myosin binding protein-C mutations in families with hypertrophic cardiomyopathy: disease expression in relation to age, gender, and long term outcome.
    Page SP; Kounas S; Syrris P; Christiansen M; Frank-Hansen R; Andersen PS; Elliott PM; McKenna WJ
    Circ Cardiovasc Genet; 2012 Apr; 5(2):156-66. PubMed ID: 22267749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of systolic dysfunction in genotyped hypertrophic cardiomyopathy.
    Fujino N; Konno T; Hayashi K; Hodatsu A; Fujita T; Tsuda T; Nagata Y; Kawashiri MA; Ino H; Yamagishi M
    Clin Cardiol; 2013 Mar; 36(3):160-5. PubMed ID: 23197398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Founder Mutation in MYBPC3: Phenotypic Comparison With the Most Prevalent MYBPC3 Mutation in Spain.
    Sabater-Molina M; Saura D; García-Molina Sáez E; González-Carrillo J; Polo L; Pérez-Sánchez I; Olmo MDC; Oliva-Sandoval MJ; Barriales-Villa R; Carbonell P; Pascual-Figal D; Gimeno JR
    Rev Esp Cardiol (Engl Ed); 2017 Feb; 70(2):105-114. PubMed ID: 28029522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy.
    Jørgenrud B; Jalanko M; Heliö T; Jääskeläinen P; Laine M; Hilvo M; Nieminen MS; Laakso M; Hyötyläinen T; Orešič M; Kuusisto J
    PLoS One; 2015; 10(8):e0134184. PubMed ID: 26267065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A human MYBPC3 mutation appearing about 10 centuries ago results in a hypertrophic cardiomyopathy with delayed onset, moderate evolution but with a risk of sudden death.
    Teirlinck CH; Senni F; Malti RE; Majoor-Krakauer D; Fellmann F; Millat G; André-Fouët X; Pernot F; Stumpf M; Boutarin J; Bouvagnet P
    BMC Med Genet; 2012 Nov; 13():105. PubMed ID: 23140321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel missense mutation in the myosin binding protein-C gene is responsible for hypertrophic cardiomyopathy with left ventricular dysfunction and dilation in elderly patients.
    Konno T; Shimizu M; Ino H; Matsuyama T; Yamaguchi M; Terai H; Hayashi K; Mabuchi T; Kiyama M; Sakata K; Hayashi T; Inoue M; Kaneda T; Mabuchi H
    J Am Coll Cardiol; 2003 Mar; 41(5):781-6. PubMed ID: 12628722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.